Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Entero Therapeutics, Inc. (ENTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ENTO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $36
1 Year Target Price $36
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.06% | Avg. Invested days 19 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.81M USD | Price to earnings Ratio - | 1Y Target Price 36 |
Price to earnings Ratio - | 1Y Target Price 36 | ||
Volume (30-day avg) 1 | Beta 0.84 | 52 Weeks Range 0.18 - 1.27 | Updated Date 06/30/2025 |
52 Weeks Range 0.18 - 1.27 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -5.21% | Return on Equity (TTM) -33.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 64221629 | Price to Sales(TTM) - |
Enterprise Value 64221629 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.1 | Shares Outstanding 4765730 | Shares Floating 4446092 |
Shares Outstanding 4765730 | Shares Floating 4446092 | ||
Percent Insiders 7.3 | Percent Institutions 3.06 |
Analyst Ratings
Rating 1 | Target Price 36 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Entero Therapeutics, Inc.
Company Overview
History and Background
Data for Entero Therapeutics, Inc. is not available, so I cannot perform the request. Founded year, significant milestones, and evolution over time are unknown.
Core Business Areas
Leadership and Structure
Insufficient data available to outline leadership team and organizational structure.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
Insufficient data available to summarize the industry.
Positioning
Insufficient data available to explain positioning.
Total Addressable Market (TAM)
TAM data not available.
Upturn SWOT Analysis
Strengths
- [
- ]
Weaknesses
- [
- ]
Opportunities
- [
- ]
Threats
- [
- ]
Competitors and Market Share
Key Competitors
Competitive Landscape
Insufficient data available to evaluate competitive advantages and disadvantages.
Growth Trajectory and Initiatives
Historical Growth: No historical growth data available.
Future Projections: No future projections available.
Recent Initiatives: No recent initiatives data available.
Summary
Insufficient data available. Without sufficient data, it is impossible to accurately assess the company's strengths, weaknesses, opportunities, and threats or determine the overall health of the company. Further analysis requires access to relevant business and financial information.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly unavailable data.
Disclaimers:
The information provided is based on the absence of available data. The analysis should not be considered financial advice. Investing in securities involves risk of loss. Information is provided 'as is' and without warranty of any kind.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entero Therapeutics, Inc.
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2016-10-11 | CEO & Director Mr. Richard Joel Paolone | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.enterothera.com |
Full time employees 2 | Website https://www.enterothera.com | ||
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. It develops Adrulipase, an oral, non-systemic, and biologic capsule that is in Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP), as well as a recombinant lipase enzyme that enables the digestion of fats and other nutrients in CF and CP patients with EPI. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.